Paclitaxel for ovarian cancer

Paclitaxel (Taxol-Bristol-Myers Squibb) is the first of a new group of cytotoxic drugs, the taxanes. It is licensed for the treatment of patients with metastatic ovarian carcinoma "where standard, platinum-containing, therapy has failed". What is its place in treatment?